Zimmer purchases biologic therapeutics company ETEX

Spinal Tech

Zimmer acquired ETEX Holdings to enhance its biologics portfolio.

"Zimmer is committed to developing the most comprehensive range of biologic therapies for patients suffering from musculoskeletal joint disease, from early intervention solutions like Gel-One Cross-linked Hyaluronate and joint preservation solutions like Zimmer Knee Creations Subchondroplasty Procedure, along with Zimmer's Chondrofix Osteochondral Allograft and Denovo NT Natural Tissue Graft personalized cartilage solutions," said Zimmer Americas CEO Joseph A. Cucolo. "ETEX's innovative bone substitute material products add more depth to a growing portfolio of solutions for the early stages of joint disease."

 

ETEX has been focused on clinical solutions to advance the orthopedic standard of care. The company's breakthrough technology is biomimetic calcium phosphate, which mimics the chemical structural features of human bone and promotes natural bone regeneration.

 

The financial terms of the transaction were not disclosed. This deal will make ETEX technology available to a broader number of surgeons.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers